Legal & General Group PLC Revance Therapeutics, Inc. Transaction History
Legal & General Group PLC
- $440 Billion
- Q2 2024
A detailed history of Legal & General Group PLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 71,199 shares of RVNC stock, worth $182,981. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71,199
Previous 83,172
14.4%
Holding current value
$182,981
Previous $409,000
55.5%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding RVNC
# of Institutions
196Shares Held
81.5MCall Options Held
490KPut Options Held
128K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$15.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...